share_log

众生药业(002317.SZ):众生睿创一类创新药RAY1225注射液降糖II期临床试验获得子研究顶线分析数据结果

Guangdong Zhongsheng Pharmaceutical (002317.SZ): The phase II clinical trial of the Innovative Drug RAY1225 injection for lowering blood sugar has obtained top-line analysis data results from the sub-study.

Gelonghui Finance ·  Dec 30, 2024 17:54

On December 30, Glonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has independently developed an innovative peptide drug, RAY1225 injection, which is used in the Phase II clinical trial for type 2 diabetes patients, and has recently obtained the top-line analysis data from the sub-study. Preliminary results indicate that RAY1225 injection has shown positive efficacy and good safety in adult participants with type 2 diabetes in China, with the trial results being ideal and achieving the expected objectives.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment